Antiviral Therapeutics: Pipelines and Competitive Dynamics

리서치사	Insight Pharma Reports
발행일	2006년 07월	상품코드	42647
페이지 정보	125 pages
가격	US $ 2,750 ￦ 3,276,600 Hard Copy US $ 3,500 ￦ 4,170,200 PDF by E-mail (Single Site License) & Hard Copy

한글목차
영문목차
관련자료

영문목차

Abstract

Antiviral Therapeutics: Pipelines and Competitive Dynamics assesses the compounds, the clinical data, the companies, and the market-shifting developments in the antiviral therapeutic category. Sales of antiviral agents currently constitute 25% of the anti-infective drug market. The ability of viruses to develop resistance against drugs, coupled with sub-optimal treatment outcomes as a result of failure of patients to comply with the full course of therapy, will continue to provide the commercial and medical incentive for intense R&D activity.

Until recently, much of the effort to develop new antiviral agents was directed toward improved agents for the treatment of HIV and Hepatitis C (HCV). While these indications continue to attract research dollars and to make measurable progress with respect to dosing, deliverability, and efficacy, several new developments have reignited interest in antiviral disease R&D. These include concern about the evolution of avian influenza into a lethal pandemic and recent approvals for vaccines against certain strains of Human Papilloma Virus (HPV) that are associated with high rates of cervical cancer.

Antiviral Therapeutics: Pipelines and Competitive Dynamics surveys the 5 major viral disease categories and their sub-indications- HIV, Hepatitis, Herpes Viruses, Human Papilloma Viruses, and Respiratory Viruses.

For each indication, the report provides:

Pathophysiology, incidence and prevalence, symptoms and sequelae.
Assessment of current treatment options.
Assessment of unmet medical need.
Assessment of compounds in development (by agent and by mechanism of action).
Profiles of companies active in antiviral R&D

Chapter 1. Viral Disorder and Therapeutic Approaches

1.1. Commom Viral Infections
1.2. Vaccines or Antiviral Drugs
1.3. Inhibition of Viral Infection of Cells
1.4. Inhibition of Viral Processing

Chapter 2. Review of Major Viral Disorders

2.1. Human Immunodeficiency Virus
2.2. Hepatitis Viruses
- Hepatitis A
- Hepatitis B
- Hepatitis C
2.3. Herpes Viruses
- Herpes Simplex Virus
- Varicella-Zoster Virus
- Cytomegalovirus
- Epstein-Barr Virus
2.4. Human Papilloma Virus
2.5. Respiratory Viruses
- Influenza
- Respiratory Syncytial Virus
- Coronaviruses

Chapter 3. Current Treatment

3.1. Human Immunodeficiency Virus
- HIV Reverse Transcriptase Inhibitors
- HIV Protease Inhibitors
- HIV Fusion Inhibitors
3.2. Hepatitis Viruses
- Vaccine Treatments
- Cytokines
- Antiviral Agents
3.3. Herpes Viruses
- Viral Replication Inhibitors
3.4. Human Papilloma Viruses
3.5. Respiratory Viruses
- Vaccines
- Neuraminidase Inhibitors
- Antibodies
- Inosine Monophosphate Dehydrogenase Inhibitors

Chapter 4. Compounds in Development: New Antiviral Agents

4.1. Human Immunodeficiency Virus
- HIV Protease Inhibitors
- Reverse Transcriptase Inhibitors
- Cell Entry Blockers
- HIV Replication Inhibitors
- HIV Integrase Inhibitors
- HIV Maturation Inhibitors
- Combination Therapies
4.2. Hepatitis C
- HCV Protease Inhibitors
- Polymerase Inhibitors
- Immunostimulants: Interferons
- Toll-like Receptor Agonists
- Other Immunoregulators
- Viral Replication Inhibitors
4.2. Mechanistic Issues in Atherogenic Dyslipidemia
- Anti-Atherogenic Effects of High-Density Lipoprotein
- Metabolic Syndrome, High-Density Lipoprotein, and Triglycerides
4.3. Hepatitis B
- DNA Polymerase Inhibitors
- Other Agents
4.4. Herpes Viruses
- Vaccines
- Viral Replication Inhibitors
- Viral Uptake Inhibitors
- DNA Synthesis Inhibitors
- Other Agents
4.5. Human Papilloma Viruses
- Vaccines
- Interferons
- Immunomodulators
4.6. Influenza
- New Drugs
- New Vaccines
- H5N1 Influenza Vaccines